pharmaphorum2 天
FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK
PT010 is based on the inhaled corticosteroid budesonide, long-acting muscarinic antagonist (LAMA) glycopyrronium and long-acting beta agonist (LABA) formoterol fumarate, and has been filed for ...
pharmaphorum5 天
Chiesi backs up COPD triple therapy with real world study
Trimbow (beclometasone+formoterol+glycopyrronium) combines an inhaled corticosteroid (ICS), a long-acting beta adrenoceptor agonist (LABA) and a long-acting muscarinic antagonist (LAMA ...
Medscape1 天
The Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome
The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...
Medscape3 天
The Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome
Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the ...